|
1
|
Kaufmann M, Hortobagyi GN, Goldhirsch A,
Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R,
Jonat W, et al: Recommendations from an international expert panel
on the use of neoadjuvant (primary) systemic treatment of operable
breast cancer: An update. J Clin Oncol. 24:1940–1949. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hayes DF, Thor AD, Dressler LG, Weaver D,
Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle
JN, et al: HER2 and response to paclitaxel in node-positive breast
cancer. New Engl J Med. 357:1496–1506. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu D, Joshi A, Li H, Zhang N, Ren MM, Gao
Y, Wada R and Jin JY: Model-based meta-analysis for quantifying
Paclitaxel dose response in cancer patients. CPT Pharmacometrics
Syst Pharmacol. 3:e1152014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seidman AD, Berry D, Cirrincione C, Harris
L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, et
al: Randomized Phase III trial of weekly compared with
every-3-weeks paclitaxel for metastatic breast cancer, with
trastuzumab for all HER-2 overexpressors and random assignment to
trastuzumab or not in HER-2 nonoverexpressors: Final results of
Cancer and Leukemia Group B protocol 9840. J Clin Oncol.
26:1642–1649. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Green MC, Buzdar AU, Smith T, Ibrahim NK,
Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera
E, et al: Weekly paclitaxel improves pathologic complete remission
in operable breast cancer when compared with paclitaxel once every
3 weeks. J Clin Oncol. 23:5983–5992. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sparano JA, Wang M, Martino S, Jones V,
Perez E, Saphner T, Wolff AC, Sledge GW Jr, Wood WC and Davidson
NE: Phase III study of doxorubicin-cyclophosphamide followed by
paclitaxel or docetaxel given every 3 weeks or weekly in operable
breast cancer: Results of Intergroup Trial E1199. Journal of
Clinical Oncology, 2007 ASCO Annual Meeting Proceedings. 25(Suppl
18): S5162007.
|
|
7
|
Vahdat L: Choosing a taxane for adjuvant
treatment of breast cancer: More than a flip of the coin? Nat Clin
Pract Oncol. 5:570–571. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kountourakis P, Missitzis I, Doufexis D,
Zobolas V, Pissakas G, Arnogiannaki N, Maliou S, Sotiropoulou A and
Ardavanis A: Neoadjuvant sequential epirubicin and docetaxel
followed by surgery-radiotherapy and post-operative docetaxel or
gemcitabine/vinorelbine combination based on primary response: A
multimodality approach for locally advanced breast cancer. J Cancer
Res Clin Oncol. 137:221–228. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smith TJ, Bohlke K, Lyman GH, Carson KR,
Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB,
Perkins CL, et al: Recommendations for the use of WBC growth
factors: American Society of Clinical Oncology clinical practice
guideline update. J Clin Oncol. 33:3199–3212. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kurosumi M, Akashi-Tanaka S, Akiyama F,
Komoike Y, Mukai H, Nakamura S and Tsuda H: Committee for
Production of Histopathological Criteria for Assessment of
Therapeutic Response of Japanese Breast Cancer Society:
Histopathological criteria for assessment of therapeutic response
in breast cancer (2007 version). Breast Cancer. 15:5–7. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno
S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, et al:
Phase II study of preoperative sequential FEC and docetaxel
predicts of pathological response and disease free survival. Breast
Cancer Res Treat. 110:531–539. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jaiyesimi IA, Buzdar AU and Hortobagyi G:
Inflammatory breast cancer: A review. J Clin Oncol. 10:1014–1024.
1992.PubMed/NCBI
|
|
14
|
Kaufmann M, von Minckwitz G, Bear HD,
Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W,
Jackesz R, et al: Recommendations from an international expert
panel on the use of neoadjuvant (primary) systemic treatment of
operable breast cancer: New perspectives 2006. Ann Oncol.
18:1927–1934. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa
P, et al: Meta-analysis results from the collaborative trials in
neoadjuvant breast cancer (CTNeoBC). Cancer Res. 72(Suppl): S1–S11.
2012.
|
|
16
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mamounas EP, Bryant J, Lembersky B,
Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G,
Soran A and Wolmark N: Paclitaxel after doxorubicin plus
cyclophosphamide as adjuvant chemotherapy for node-positive breast
cancer: Results from NSABP B-28. J Clin Oncol. 23:3686–3696. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harris LN, Broadwater G, Lin NU, Miron A,
Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, et al:
Molecular subtypes of breast cancer in relation to paclitaxel
response and outcomes in women with metastatic disease: Results
from CALGB 9342. Breast Cancer Res. 8:R662006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Denkert C, Huober J, Loibl S, Prinzler J,
Kronenwett R, Darb-Esfahani S, Brase JC, Solbach C, Mehta K,
Fasching PA, et al: HER2 and ESR1 mRNA expression levels and
response to neoadjuvant trastuzumab plus chemotherapy in patients
with primary breast cancer. Breast Cancer Res. 15:R112013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
de Azambuja E, Holmes AP, Piccart-Gebhart
M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I,
Smith I, et al: Lapatinib with trastuzumab for HER2-positive early
breast cancer (NeoALTTO): Survival outcomes of a randomised,
open-label, multicentre, phase 3 trial and their association with
pathological complete response. Lancet Oncol. 15:1137–1146. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gianni L, Pienkowski T, Im YH, Roman L,
Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J,
Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and
trastuzumab in women with locally advanced, inflammatory, or early
HER2-positive breast cancer (NeoSphere): A randomised multicentre,
open-label, phase 2 trial. Lancet Oncol. 13:25–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Robidoux A, Tang G, Rastogi P, Geyer CE
Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L,
Sarwar S, et al: Lapatinib as a component of neoadjuvant therapy
for HER2-positive operable breast cancer (NSABP protocol B-41): An
open-label, randomised phase 3 trial. Lancet Oncol. 14:1183–1192.
2013. View Article : Google Scholar : PubMed/NCBI
|
